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John W. SweetenhamFunctional imaging with [18F] fluorodeoxyglucose-
positron emission tomography (FDG-PET) is emerg-
ing as a useful technique in the management of patients
with Hodgkin’s lymphoma (HL). In addition to its use
as a stagingmodality, there is increasing evidence for its
role as a prognostic and predictive tool in patients
undergoing first-line therapy for this disease [1-4].
Several studies have shown that the results of
PET scans performed at the completion of induction
therapy are prognostic for subsequent disease-free
survival (DFS). Prospective studies are currently
evaluating the use of posttreatment FDG-PET to
select patients for consolidative radiation therapy,
restricting this modality to those patients with
PET-positive residual masses, thereby reducing the
potential for late toxicity.
The use of "early" interim PET scanning has been
evaluated in retrospective studies, in which it has been
shown that PET scans performed after 1 or 2 cycles
of standard induction therapy are highly predictive
of subsequent response rates and DFS [1-3]. The
concept of using FDG-PET scans as a ‘‘biomarker’’ of
early chemoresistance is now being tested in prospective
studies in which patients who are "PET positive" early
in their treatment courses, receive intensified therapy.
No mature data are available from these studies, many
of which are on going.
Based on experience in the front-line setting, several
groups have evaluated FDG-PET as a prognostic tool
in patients with HL undergoing high-dose therapy
and autologous stem cell transplantation (ASCT) for re-
lapsed and refractory disease [5-8]. The report from
Smeltzer et al. [9] represents the latest of these. Of
106 patients who underwent ASCT at their institutions
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scans after salvage therapy with a standard second-line
regimen, but before ASCT. They report 3-year event-
free survival (EFS) of 82% for those who were PET-
negative going into transplantation versus 41% for
those who were PET positive. A trend for improved
overall survival was observed in the PET-negative
group. In their univariate and multivariate analyses,
this group applied established prognostic models
such as those reported previously from Memorial
Sloan-Kettering Cancer Center and the International
Prognostic Factors Project, none ofwhichwas prognos-
tic. Pre-ASCT PET status was the only prognostic
factor for 3-year EFS after transplantation.
The results from this study are comparable to
several other series and taken together, they suggest
that FDG-PET may be a powerful prognostic tool,
which could be applied to the selection of patients
for ASCT or to select high-risk patients for posttrans-
plantation consolidation or maintenance therapy.
This study also shares the same limitations as the
other published series. The first challenge is whether
or not the overall treatment plan should be changed
based upon the result of the pretransplantation PET
scan. In most series, the long-term EFS or DFS rates
for patients with PET-positive disease are in the
30% to 40% range—not spectacular, but better
than standard dose salvage therapy alone, and it
would be difficult to deny these patients potentially
curative therapy based on the result of the PET
scan. Another issue this raises is whether patients
who are PET positive should ‘‘switch’’ to an alter-
nate salvage regimen. There are few data to support
this approach, although at least 1 single institution
study has suggested that changing salvage regimens
with the goal of achieving a negative PET before
ASCT may result in improved long-term outcome
[7]. This has not been confirmed in other studies.
Another potential approach might be to consider
allogeneic transplantation for patients who are
PET positive after salvage therapy. The high
regimen-related mortality of this approach is diffi-
cult to justify in this population with projected
cure rates in the 30% to 40% range.
Pretransplantation PET may have greater clinical
utility in selecting poor-risk patients for additional1569
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maintenance treatments. Several novel agents, includ-
ing brentuzimab vedotin and lenalidomide, are being
evaluated in the posttransplantation setting. At the
moment, selection of poor-risk patients for this ap-
proach is based on ‘‘conventional’’ prognostic factors,
although PET is likely to replace this.
There is also uncertainty about the optimal timing
of the FDG-PET scan. The International Harmoniza-
tion Project on Lymphoma recommends that response
assessment should be performed 6 to 8 weeks after
completion of chemotherapy to minimize the risk of
false-positive results [10]. This is not realistic within
the context of ASCT, where physicians wish to limit
the delay between completion of salvage therapy and
transplantation.
It is possible that a PET performed after ASCT
may be more prognostic than a pretransplantation
study, but this has not yet been systematically investi-
gated and timing again becomes an issue—20% to
25% of relapses after ASCT occur within the first 2
months, so it would not make sense to hold mainte-
nance therapy until a restaging scan is performed 6
to 8 weeks posttransplantation.
Interpretation of PET scans is still problematic,
although a consensus is emerging, but this may also
complicate studies of the utility of PET in the peri-
transplantation setting.
In summary, the data from Smeltzer et al. [9] pro-
vide important confirmatory information and add to
the emerging evidence that PET should be regarded
as a major prognostic factor for patients with HL
undergoing transplantation and should probably re-
place ‘‘conventional’’ prognostic factors in selection
of patients for trials of novel posttransplantation strat-
egies. Whether achieving ‘‘PET negativity’’ should be
the goal of pretransplantation salvage is not yet clear;
this requires further prospective study.ACKNOWLEDGMENTS
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